IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.
What IOL files
- Others59
- Investor Meet36
- Updates24
- Important24
- Board Meeting9
- PPTs6
IOL Chemicals is expanding its Ibuprofen capacity by 6,000 MTPA to 18,000 MTPA with a ₹350 Cr investment. It is also entering the CDMO formulation space with a ₹110 Cr facility and establishing a dedicated specialty chemicals plant for ₹35 Cr, entirely funded via internal accruals.
IOL Chemicals reports record Q1 FY27 results: Revenue up 37.1% to ₹756.3 Cr, PAT surged 89.9% to ₹64.5 Cr. Performance driven by improved capacity utilization, product mix. Clopidogrel API received NMPA approval in China, expanding market access.
IOLCP secured approval from China's NMPA for its Clopidogrel Bisulfate API. This boosts the company's access to the massive Chinese pharmaceutical market, enhancing its global footprint for this key product.
IOL Chemicals & Pharma is urging shareholders to claim unpaid dividends to prevent their transfer, along with corresponding shares, to the IEPF. Physical shareholders must also update KYC details to facilitate dividend payments.
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about General Updates